Related Experiment Video
Updated: Feb 17, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies
1Department of Transplant Hepatology, Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Insights
Hepatitis C genotype 3 (HCV-3) is common in Asia and difficult to treat. New, highly effective, interferon-free regimens are now available, with recent cost reductions improving global accessibility for this challenging Hepatitis C virus variant.
Area of Science:
- Hepatology and Viral Gastroenterology
- Infectious Diseases and Public Health
- Pharmacological Innovations
Background:
- Hepatitis C virus genotype 3 (HCV-3) is prevalent in Asia, causing severe liver fibrosis, cirrhosis, and hepatocellular carcinoma.
- HCV-3 is challenging to treat, particularly in patients with prior treatment experience or cirrhosis, leading to significant morbidity and mortality.
- Traditional therapies like pegylated interferon and ribavirin have limited efficacy and severe side effects, necessitating novel treatment strategies.
Purpose of the Study:
- To discuss the latest advancements in antiviral therapies for HCV-3.
- To provide a treatment outline for HCV-3 prevalent regions, focusing on novel drug combinations.
- To highlight recent progress in reducing drug costs and enhancing global accessibility of effective HCV-3 treatments.
Main Methods:
- Review of recent clinical studies and drug development pipelines for Hepatitis C virus.
- Analysis of emerging interferon-free treatment regimens incorporating direct-acting antivirals (DAAs).
- Examination of economic factors and strategies aimed at cost reduction for HCV therapies.
Main Results:
- Development of highly effective interferon-free regimens, including sofosbuvir-based combinations, offering improved cure rates.
- Significant breakthroughs in reducing the cost of novel HCV drugs, making them more accessible.
- Increased awareness and potential for wider implementation of advanced HCV-3 therapies in resource-limited settings.
Conclusions:
- Novel direct-acting antiviral regimens represent a paradigm shift in managing HCV-3, offering superior efficacy and tolerability.
- Cost-effective strategies are crucial for global accessibility, particularly in high-prevalence Asian countries.
- Continued research and collaborative efforts are needed to ensure widespread availability and eradication of HCV-3.
Abstract:
Hepatitis C virus (HCV) is known to cause chronic hepatitis C, and its sequelae of cirrhosis and hepatocellular carcinoma. Hepatitis C genotype 3 (HCV-3) in particular is notorious for causing accelerated liver fibrosis, cardiovascular, and metabolic effects, thus increasing morbidity and mortality. It is the commonest variant in Asian countries like India and Pakistan. It is also one of the hardest-to-treat genotypes, especially among treatment-experienced and cirrhotic patients. Due to limited health care affordability and accessibility in these areas, many patients remain untreated. Until recently, the established therapy for HCV had been a combination of pegylated interferon + ribavirin. However, it was only effective in about half of patients and had severe adverse effects; hence a more efficacious option needed to be found. Recent advances have led to the development of sofosbuvir, an NS5B inhibitor that is fast becoming the standard of care, in combination with other novel drugs. It was initially marketed at $1,000 per pill, a cost that was too high for most. Thus, it has not been utilized as a global therapy as yet. Formulation of effective interferon-free regimens is a huge milestone, and awareness needs to be raised regarding these new highly effective options in both the physician and the patient population. This article discusses the newest drugs and combinations that have been developed in the fight against HCV-3, as a treatment outline for HCV-3-dominant areas. It also highlights recent breakthroughs in cost reductions of these drugs and the effort to make them globally accessible.
How To Cite This Article:
Saeed N, Gurakar A. Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. Euroasian J Hepato-Gastroenterol 2016;6(1):35-42.
